Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Xcovery's Ensartinib Extends PFS in First-Line Advanced ALK-Positive NSCLC

Xcovery's Ensartinib Extends PFS in First-Line Advanced ALK-Positive NSCLC

Aug 10, 2020
|
staff reporter

NEW YORK – Xcovery's ensartinib significantly extended progression-free survival in advanced, ALK-positive non-small cell lung cancer patients compared to crizotinib (Pfizer's Xalkori), researchers reported at a medical conference last week.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Featured Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Featured Webinar

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. 

What's Popular?

In Cancer

  1. NCI Director Sharpless Outlines Ideas to Aggressively Lower Cancer Deaths

  2. Verastem Oncology's Combination Therapy Advances in KRAS-Mutated Lung Cancer

    Premium

  3. Carisma Therapeutics Taps Into Innate Immune System to Extend CAR Therapy to Solid Tumors

    Premium

  4. Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

  5. AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.